Compare Pfizer with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs AUROBINDO PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER AUROBINDO PHARMA PFIZER/
AUROBINDO PHARMA
 
P/E (TTM) x 32.4 10.5 308.9% View Chart
P/BV x 5.4 2.3 238.5% View Chart
Dividend Yield % 0.6 0.6 114.2%  

Financials

 PFIZER   AUROBINDO PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
AUROBINDO PHARMA
Mar-18
PFIZER/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs2,365809 292.3%   
Low Rs1,625504 322.4%   
Sales per share (Unadj.) Rs430.3281.1 153.1%  
Earnings per share (Unadj.) Rs78.741.4 190.3%  
Cash flow per share (Unadj.) Rs93.250.9 183.2%  
Dividends per share (Unadj.) Rs20.002.50 800.0%  
Dividend yield (eoy) %1.00.4 263.3%  
Book value per share (Unadj.) Rs586.5199.4 294.2%  
Shares outstanding (eoy) m45.75585.88 7.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.62.3 198.5%   
Avg P/E ratio x25.315.9 159.7%  
P/CF ratio (eoy) x21.412.9 165.9%  
Price / Book Value ratio x3.43.3 103.3%  
Dividend payout %25.46.0 420.4%   
Avg Mkt Cap Rs m91,271384,630 23.7%   
No. of employees `0002.617.3 15.2%   
Total wages/salary Rs m3,14321,308 14.7%   
Avg. sales/employee Rs Th7,484.89,500.7 78.8%   
Avg. wages/employee Rs Th1,195.01,229.4 97.2%   
Avg. net profit/employee Rs Th1,369.11,397.9 97.9%   
INCOME DATA
Net Sales Rs m19,685164,666 12.0%  
Other income Rs m1,1431,020 112.1%   
Total revenues Rs m20,828165,686 12.6%   
Gross profit Rs m5,00337,718 13.3%  
Depreciation Rs m6635,580 11.9%   
Interest Rs m4777 0.5%   
Profit before tax Rs m5,47932,380 16.9%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8788,183 23.0%   
Profit after tax Rs m3,60124,229 14.9%  
Gross profit margin %25.422.9 111.0%  
Effective tax rate %34.325.3 135.7%   
Net profit margin %18.314.7 124.3%  
BALANCE SHEET DATA
Current assets Rs m24,167121,878 19.8%   
Current liabilities Rs m9,54486,806 11.0%   
Net working cap to sales %74.321.3 348.8%  
Current ratio x2.51.4 180.3%  
Inventory Days Days55130 42.4%  
Debtors Days Days2968 42.0%  
Net fixed assets Rs m9,51481,037 11.7%   
Share capital Rs m458586 78.1%   
"Free" reserves Rs m26,375116,218 22.7%   
Net worth Rs m26,832116,804 23.0%   
Long term debt Rs m254,512 0.6%   
Total assets Rs m36,900211,052 17.5%  
Interest coverage x1,305.542.7 3,060.1%   
Debt to equity ratio x00 2.4%  
Sales to assets ratio x0.50.8 68.4%   
Return on assets %9.811.8 82.5%  
Return on equity %13.420.7 64.7%  
Return on capital %20.427.4 74.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2280,727 0.0%   
Fx outflow Rs m1,48934,700 4.3%   
Net fx Rs m-1,46646,027 -3.2%   
CASH FLOW
From Operations Rs m3,31819,548 17.0%  
From Investments Rs m-2,383-19,570 12.2%  
From Financial Activity Rs m-1,1048,642 -12.8%  
Net Cashflow Rs m-1698,922 -1.9%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 8.0 94.3%  
FIIs % 4.9 27.7 17.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 10.2 232.4%  
Shareholders   85,207 69,601 122.4%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   WOCKHARDT  J.B.CHEMICALS  PROCTER & GAMBLE HEALTH  DIVIS LABORATORIES  FULFORD INDIA  

Compare PFIZER With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Oct 15, 2019 03:37 PM

TRACK PFIZER

PFIZER - TORRENT PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS